The Medtronic (NYSE:MDT) diabetes business sputtered in the fourth quarter but could be bolstered by a major regulatory nod this year. The Fridley, Minnesota-based company saw revenues for its diabetes arm fall by 7.7% year-over-year in the fourth quarter amid overall misses on both sales and adjusted earnings per share compared to Wall Street’s expectations. […]
Diabetes
Bigfoot Biomedical adds former Insulet VP as chief commercial officer
Bigfoot Biomedical announced today that it appointed former Insulet executive Matt Rainville as its chief commercial officer. Rainville’s role includes leading the growth of Milpitas, California–based Bigfoot Biomedical’s fully commercial Bigfoot Unity diabetes management program as the company looks to expand access to its offerings. Bigfoot Unity aims to simplify CGMs and the data they produce […]
Glucose monitor maker Know Labs expands leadership team
Non-invasive glucose monitor developer Know Labs (OTCQB:KNWN) announced today that it added two executives to its leadership team. Seattle-based Know Labs — which aims to make the first non-invasive glucose monitor cleared by the FDA — added Steven Kent as its new chief product officer, along with Peter Conley as its CFO and SVP of […]
How Glytec is advancing insulin management in the hospital
Growth and new partnerships have Glytec excited for the future of its Glucommander insulin dosing decision support software. After years of running a hospitalist group and mentoring hospitals on quality improvement, blood clot prevention and more, Dr. Jordan Messler found himself falling into a lot of work on diabetes. Messler cut his teeth on quality improvement around […]
Report: Dexcom in talks to acquire Insulet
Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD). Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg’s sources preferred to remain anonymous […]
Labcorp launches at-home collection device for diabetes risk testing
Labcorp (NYSE:LH) announced today that it launched an at-home collection kit that measures HbA1c from a small blood sample. Burlington, North Carolina-based Labcorp’s first-of-its-kind diagnostic offering uses a collection device from Weavr Health and is offered through its Labcorp OnDemand platform. Get the full story at our sister site, Drug Delivery Business News.
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented […]
Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
The future for Insulet (Nasdaq:PODD) has a different look than it did about a week ago. A massive shake-up at the executive level came on May 5 when Shacey Petrovic announced she would step down as president and CEO for personal reasons. Petrovic will stay on as a board member at the Acton, Massachusetts-based automated insulin […]
Senseonics beats The Street in Q1 following Eversense E3 launch
Senseonics (NYSE:SENS) posted first-quarter results that topped the consensus revenue forecast on Wall Street. The Germantown, Maryland-based company posted profits of $86.7 million, or 19¢ per share, on sales of $2.5 million for the three months ended March 31, 2022, for a massive bottom-line gain from losses of $249.5 million this time last year despite a […]
Shacey Petrovic to step down as Insulet CEO, ResMed exec Jim Hollingshead to take role
Insulet (Nasdaq:PODD) announced today that President and CEO Shacey Petrovic will step down for personal family reasons. Petrovic will step down from her position effective June 1, 2022, but will continue to serve on the company’s board. She will also serve as an advisor to the company through May 2023 to support the leadership transition to […]
Insulet posts Street-beating Q1 as Omnipod 5 rollout is ‘progressing very well’
Insulet (Nasdaq:PODD) shares were down after hours despite first-quarter results that topped the consensus forecast. The Acton, Massachusetts-based automated insulin technology developer posted profits of $27.8 million, or 40¢ per share, on sales of $295.4 million for the three months ended March 31, 2022, for a big bottom-line gain from breakeven this time a year ago […]
